Repaglinide insulin secretagogues

AG-EE 623 ZW - AG-EE 388 - Prandin - GlucoNorm - NovoNorm - AG-EE 388 ZW - repa-glinide



Trial Studied treatment Control Patients Size Study type Results NCT

Diabetes type 2 - antidiabetic drugs in all types of patients - insulin secretagogues in all type of patients - antidiabetic drugs in patients inadequately controlled on metformin - antidiabetic drugs in patients inadequately controlled on monotherapy - insulin secretagogues - Meglitinides (glinides) in all types of patients

Moses, 1999repaglinidecontrol (add on MET)54 (27/27) Exploratory
Landgraf, 1999repaglinideglibenclamideNA
Marbury, 1999repaglinideglibenclamideNA
Wolffenbuttel, 1999repaglinideglibenclamide320 (211/109)
Madsbad, 2001repaglinideglipizide256
Lund, 2007repaglinidemetforminNA
Raskin, 2001repaglinideon top pioglitazoneNA
Raskin, 2001repaglinideon top rosiglitazoneNA
Raskin, 2000repaglinideon top troglitazone256
Goldberg, 1998repaglinideplacebo99 (66/33) Exploratory
Jovanovic, 2000repaglinideplacebo361 (286/75)
Chuang, 1999repaglinideplaceboNA
Landin-Olsson, 1999repaglinideplacebo (on top bedtime NPH-insulin)NA